This page shows the publications co-authored by Richard Stone and Robert Lindsley.
Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML). Blood. 2019 Nov 13; 134(Supplement_1):15.
Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. Blood Adv. 2017 Sep 26; 1(21):1786-1789.
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76.
Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction. Am J Hematol. 2021 Apr 10.
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.